A new research perspective titled "Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification" has been published in Oncotarget. In ...
Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: A randomized controlled trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a ...
Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a ...
The blood pressure medication enalapril did not prevent cardiotoxicity among patients with cancer being treated with chemotherapy. The angiotensin-converting enzyme (ACE) inhibitor enalapril, a common ...
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity. This is an ASCO ...
Healthy gut microbiome before chemo could help protect breast cancer patients against cardiotoxicity
New research suggests that a healthy microbiome before chemotherapy could help protect breast cancer patients against heart damage, or cardiotoxicity, as a result of cancer therapy. Researchers found ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results